IVD Registration in India

IVDs are regulated under the same Medical Devices Rules, 2017 that govern medical devices, but they occupy their own lane within that framework. They are classified on a four-tier risk scale using diagnostic-specific criteria, they are licensed through parallel routes for domestic manufacture and import, and their applications rely far more heavily on performance evidence than device applications do. Understanding that an IVD is regulated as a distinct kind of product — not just another device — is the starting point for getting its registration right.

This dual nature means an IVD company has to think like both a manufacturer and a diagnostician. The plant, the quality system and the validation matter as they would for any regulated product, but the performance of the assay — whether it detects what it claims, reliably, on the samples it will actually meet — is the thing the regulator is ultimately assessing. We hold both sides of that in view, so neither the manufacturing story nor the performance story is neglected in favour of the other.

• IVDs are regulated under the Medical Devices Rules, 2017.
• Classified A–D on diagnostic-specific risk criteria.
• Applications rely heavily on analytical and clinical performance.

IVD classification turns on what the test detects and what happens if it is wrong. A general-purpose reagent or a simple instrument may sit at the low-risk Class A end; a test whose result carries serious consequences — screening donated blood for transmissible agents, or guiding a critical treatment decision — sits at the high-risk Class C or D end. The class drives which authority licenses the product, how deep the performance evidence must go, and how long the process takes, so it is the first and most consequential judgement in any IVD project.

The subtlety is that two superficially similar kits can fall in different classes depending on their intended use and the decision they drive. We classify against CDSCO’s IVD categorisation with the actual intended use firmly in mind, and document the reasoning, so the application is built for the right class from the outset rather than being redirected — expensively — when a reviewer reads the classification differently. Getting this keystone right is what keeps the rest of the project on course.

For companies making IVDs domestically, the licensing pathway parallels the device manufacturing route. Lower-risk IVDs are licensed by the State Licensing Authority on a lighter, often self-declaration basis, while higher-risk kits are licensed centrally by CDSCO after a physical audit of the manufacturing site. That audit examines the facility, the environmental and contamination controls appropriate to diagnostic manufacture, the quality system, and the validation — much as it would for a device plant, but attuned to the particular demands of making reagents and kits.

We support domestic IVD manufacturers across this pathway: mapping the route by class, helping design and document a facility and quality system that will pass audit, preparing the technical and performance dossier, and managing the licensing through to grant. Setting up IVD manufacturing is a real undertaking, and doing it with the audit and the performance evidence in view from the start is what turns it from a daunting prospect into a controlled project.

For companies importing IVDs, the route runs through an Authorized Indian Representative and an import registration, and here the performance evidence takes centre stage. CDSCO wants to see robust analytical performance and, for higher-risk kits, clinical performance — and a recurring question is whether that performance holds on Indian samples. For tests with population-dependent behaviour or for locally prevalent conditions, bridging or local performance evaluation may be expected before the registration is granted.

We assess up front whether your kit is likely to need Indian data and, if so, help design and coordinate the evaluation — often under a test licence that brings the kits in for that purpose — so it reinforces the registration rather than surfacing as a mid-review demand. The import IVD route has real subtleties around performance and Indian data, which is why we cover it in more depth in our dedicated IVD import registration service for companies whose focus is specifically importing.

• Import runs through an Authorized Indian Representative.
• Analytical and clinical performance are the heart of the file.
• Indian-population bridging data may be required for some kits.

Reagents and kits are frequently temperature-sensitive, and India’s climate and distribution put genuine stress on the cold chain. CDSCO expects stability data supporting the shelf life and storage conditions you claim, and increasingly wants confidence that the product survives the conditions it will actually face in Indian logistics — not merely a European cold-room baseline. A shelf-life claim that the stability evidence cannot fully support is an easy point for a reviewer to press.

We make sure your stability and transport evidence align with your labelled storage conditions and shelf life, and that the claim on the pack is one the data can defend. For diagnostics, where a reagent that has degraded in transit can quietly give wrong results, this is not just a documentation exercise — it is part of ensuring the test performs in the field as it did in validation, which is the whole point of the product.

The IVD field moves quickly, and its more advanced products carry expectations a standard approach misses. Molecular and genetic assays raise particular questions around analytical validation, controls and reference methods; companion diagnostics that guide drug decisions sit at the high-risk end and are scrutinised on clinical performance; point-of-care tests used by non-specialists have to prove they perform in untrained hands and rougher settings. Each of these needs the evidence framed to answer the questions the reviewer will actually ask.

We bring experience of these harder cases, so a molecular kit’s controls, a companion diagnostic’s clinical concordance, or a point-of-care test’s usability are addressed in the dossier before they become deficiency questions. For a genuinely novel diagnostic with no obvious comparator, we also help frame the evidence so a reviewer can place it — often half the challenge with new technology. The through-line is the same across every IVD: build the registration around the performance story, because for a diagnostic, performance is the product.